Get the Stockscreener App
1.58
1.94%
0.03
After Hours:
1.51
-0.07
-4.43%
Psyence Biomedical Ltd stock is traded at $1.58, with a volume of 331.05K.
It is up +1.94% in the last 24 hours and down -38.04% over the past month.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
See More
Previous Close:
$1.55
Open:
$1.5219
24h Volume:
331.05K
Relative Volume:
0.29
Market Cap:
$2.96M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.23%
1M Performance:
-38.04%
6M Performance:
-65.91%
1Y Performance:
-90.28%
1-Day Range:
$1.485
$1.63
1-Week Range:
$1.45
$1.82
52-Week Range:
$1.41
$62.72
Psyence Biomedical Ltd Stock (PBM) Company Profile
Compare PBM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
1.58 | 2.90M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Psyence Biomedical Ltd Stock (PBM) Latest News
Psyence Biomedical Ltd. (PBM) -5.7% in After-hours: Despite No Clear Catalyst - Stocks Telegraph
Psyence BioMed Advances Phase IIb Clinical Trial and Expands Board - MSN
Check out these key findings about Psyence Biomedical Ltd (PBM) - setenews.com
Rapid Surge: Psyence Biomedical’s Unexpected Stock Movement - StocksToTrade
Psyence BioMed (PBM) Stock: Drives Forward with Phase IIb Trial and Unique Longevity Science Position - parameter.io
Psyence Biomedical Ltd. (PBM) Stock: Drops, But Company Pushes Forward with Groundbreaking Psychedelic Therapies - parameter.io
Psyence BioMed (Nasdaq: PBM) advances Phase IIb trial, ibogaine supply leadership - Stock Titan
Bull Run: Why Psyence Biomedical Ltd stock appeals to dividend seekersTrade Performance Summary & Long-Term Growth Portfolio Plans - moha.gov.vn
How Psyence Biomedical Ltd. Equity Warrant stock benefits from global expansionJuly 2025 Market Mood & Reliable Entry Point Alerts - Newser
Will Psyence Biomedical Ltd. Equity Warrant stock remain a Wall Street favoriteWeekly Gains Report & Reliable Volume Spike Trade Alerts - Newser
Will Psyence Biomedical Ltd. Equity Warrant stock sustain high P E ratiosAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
Is Psyence Biomedical Ltd. stock attractive for growth ETFsPortfolio Risk Report & Reliable Entry Point Trade Alerts - Newser
Price to earnings ratio of Psyence Biomedical Ltd. Warrant 20242028 on Psyence Biomedical – NASDAQ:PBMWW - TradingView
Psyence Biomedical (PBM) Stock Analysis Report | Financials & Insights - Benzinga
Psyence Biomedical (NASDAQ:PBM) Trading Down 2.5% – Should You Sell? - Defense World
Psyence Biomedical Ltd. (PBM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Psyence Biomedical : The Future of Human Longevity Will Be Transformational – And Nature May Hold the Key - marketscreener.com
How geopolitical tensions affect Psyence Biomedical Ltd. stockWeekly Trade Report & Safe Capital Growth Tips - BỘ NỘI VỤ
Psyence BioMed leads longevity research on psilocybin - Longevity.Technology
How Psyence Biomedical Ltd. stock performs in weak economyJuly 2025 Spike Watch & Reliable Breakout Forecasts - BỘ NỘI VỤ
Its Stock Has Paid Off Big Time For Psyence Biomedical Ltd - Setenews
Breakout Move: Why Psyence Biomedical Ltd. Equity Warrant stock is popular among millennialsEntry Point & Safe Capital Growth Stock Tips - moha.gov.vn
Psyence Biomedical launches psilocybin longevity research program By Investing.com - Investing.com Nigeria
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program - Asianet Newsable
Psyence Biomedical launches psilocybin longevity research program - Investing.com
Psyence BioMed Expands Ibogaine Operations in Africa with Strategic Investment - MSN
Psyence Biomedical Ltd. (PBM) -13.37% in Normal Trading: Decline Amid Recent Breakthrough Announcement - Stocks Telegraph
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
[6-K] PSYENCE BIOMEDICAL LTD. Current Report (Foreign Issuer) | PBM SEC FilingForm 6-K - Stock Titan
Psyence Biomedical Reports Strong Financial Growth in Latest Interim Results - MSN
Will Psyence Biomedical Ltd. stock rally after Fed decisionsPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Is Psyence Biomedical Ltd. stock in correction or buying zoneWeekly Trading Summary & Weekly Setup with ROI Potential - newser.com
The time has not yet come to remove your chips from the table: Psyence Biomedical Ltd (PBM) - Setenews
How Psyence Biomedical Ltd. Equity Warrant stock reacts to job market dataJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
Psyence BioMed secures sustainable iboga supply for clinical research By Investing.com - Investing.com Nigeria
[424B3] PSYENCE BIOMEDICAL LTD. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Is PBM’s Market Boost a Fleeting Mirage? - StocksToTrade
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025 - ts2.tech
Is It Time to Buy PBM Stock? - timothysykes.com
Psyence BioMed secures sustainable iboga supply for clinical research - Investing.com
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets - The Manila Times
Psyence BioMed Reaches Major Breakthrough in - GlobeNewswire
Institutional scanner results for Psyence Biomedical Ltd. Equity WarrantMarket Growth Report & Reliable Price Breakout Alerts - newser.com
Psyence Biomedical Ltd Stock (PBM) Financials Data
There is no financial data for Psyence Biomedical Ltd (PBM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):